ANI Pharmaceuticals (NASDAQ:ANIP) Posts Quarterly Earnings Results, Beats Expectations By $0.77 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) released its earnings results on Friday. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77, FiscalAI reports. ANI Pharmaceuticals had a net margin of 8.87% and a return on equity of 27.97%. The company had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter last year, the business earned $1.70 EPS. The business’s revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals updated its FY 2026 guidance to 9.190-9.690 EPS.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI raised its 2026 guidance, now targeting $1.08B–$1.14B in revenue, $285M–$300M adjusted EBITDA and $9.19–$9.69 adjusted EPS, driven by rare disease strength.
• Cortrophin Gel revenue grew 42% YoY to $75.1M in Q1, April saw the highest new patient starts since launch, and a 64‑rep commercial expansion into primary care and podiatry is being deployed to accelerate H2/2026 and 2027 growth.
• ANI recognized a $15M upfront fee from an out‑license to Harmony Biosciences, expects an additional $10M in near‑term development milestones (Q2–Q3) and low‑single‑digit royalties on pitolisant (WAKIX), adding immediate cash and future royalty upside.
• Generics continue to fund growth with Q1 generics revenue of $105.4M (up 7%), six new launches YTD and a steady 10–15 launch cadence, while management authorized a new $100M share repurchase program as part of disciplined capital allocation.
• Q1 results were impacted by insurance reverification delays and weather‑related office closures that temporarily depressed early‑quarter Cortrophin volumes and contributed to a lower non‑GAAP gross margin (60.8%), and ILUVIEN still faces ongoing Medicare access challenges.

ANI Pharmaceuticals Price Performance

Shares of ANIP traded down $2.05 during trading hours on Friday, reaching $81.86. The company had a trading volume of 1,307,703 shares, compared to its average volume of 297,488. The firm has a 50 day simple moving average of $76.82 and a 200-day simple moving average of $81.01. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 13.17 and a beta of 0.46. ANI Pharmaceuticals has a 12-month low of $56.71 and a 12-month high of $99.50.

Insiders Place Their Bets

In other news, SVP Thomas Andrew Rowland sold 4,772 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $74.91, for a total value of $357,470.52. Following the completion of the transaction, the senior vice president owned 38,730 shares in the company, valued at $2,901,264.30. This trade represents a 10.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Christopher Mutz sold 5,323 shares of the stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $78.02, for a total transaction of $415,300.46. Following the completion of the transaction, the insider owned 84,840 shares of the company’s stock, valued at $6,619,216.80. This represents a 5.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 27,860 shares of company stock worth $2,111,581. Insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently made changes to their positions in ANIP. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the 1st quarter valued at about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after acquiring an additional 423 shares in the last quarter. Jane Street Group LLC purchased a new position in ANI Pharmaceuticals during the 1st quarter valued at about $2,706,000. Finally, Norges Bank purchased a new position in ANI Pharmaceuticals during the 2nd quarter valued at about $625,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals News Summary

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat Wall Street expectations on both earnings and revenue, reporting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. The company also said quarterly revenue rose 20.5% year over year, signaling solid underlying growth. Article Title
• Positive Sentiment: The company raised its FY 2026 EPS guidance to $9.19-$9.69, above the consensus estimate of $8.79, which suggests management sees stronger profitability ahead. Article Title
• Neutral Sentiment: Investors are also parsing the earnings call transcript and presentation for details on the company’s growth drivers and updated strategy, but the main stock catalyst today is the beat-and-raise quarter. Article Title
• Neutral Sentiment: ANI also issued revenue guidance around $1.1 billion for FY 2026, roughly in line with expectations, so the revenue outlook appears stable rather than a fresh upside surprise. Article Title

Analyst Ratings Changes

Several analysts have recently commented on ANIP shares. Guggenheim raised their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.